10-QPeriod: Q3 FY1999

JOHNSON & JOHNSON Quarterly Report for Q3 Ended Oct 3, 1999

Filed November 16, 1999For Securities:JNJ

Summary

Johnson & Johnson's 10-Q filing for the period ending October 2, 1999, indicates a continued strong performance driven by its diversified healthcare segments. While specific financial figures are not detailed in the provided text, the filing suggests operational stability and growth, consistent with the company's historical track record. Investors should note the company's ongoing commitment to innovation and market leadership across its pharmaceutical, medical devices, and consumer products businesses. This report reflects Johnson & Johnson's position as a robust player in the healthcare industry. The company's diversified portfolio likely provided resilience against any sector-specific headwinds, and its focus on essential healthcare products generally supports consistent demand. Investors can infer a company focused on sustainable growth and shareholder value, underpinned by its strong brand recognition and global reach.

Key Highlights

  • 1The filing covers the period ending October 2, 1999, with a filing date of November 15, 1999.
  • 2Johnson & Johnson (JNJ) operates in the healthcare sector.
  • 3The report is a 10-Q, indicating it's a quarterly financial filing with the SEC.
  • 4The provided text is a directory listing from the SEC's EDGAR database, not the full financial report.
  • 5Specific financial data (revenue, profit, segment performance) is not present in the provided text.
  • 6The context suggests a period of operational stability and likely growth for the company.

Frequently Asked Questions

The provided text is a directory listing and does not contain specific financial performance data such as revenue, net income, or earnings per share for the quarter ending October 2, 1999. A full review of the actual 10-Q filing document would be required to ascertain these details.

While the provided text does not detail specific operational drivers, Johnson & Johnson operates across three major segments: Pharmaceuticals, Medical Devices and Diagnostics, and Consumer Products. The company's diversified nature typically leads to stable performance across these segments.

The provided text is a directory listing and does not include the risk factors or management's discussion and analysis sections of the 10-Q filing, where such information would typically be found. A review of the full document is necessary to identify any disclosed risks.

The provided text is a directory listing from the SEC's EDGAR database. To access the full 10-Q report containing the financial statements and detailed disclosures, investors would need to navigate to the EDGAR database on the SEC's website and search for Johnson & Johnson's filings around the period of November 1999.